TL;DR
BPC-157 is a 15-amino-acid synthetic peptide derived from a gastric juice protein; its published research is strongest in tendon, ligament, and gastrointestinal models. TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4); its literature base is strongest in dermal wound healing and cardiac tissue. They are frequently used together in research settings because their mechanisms are complementary rather than redundant — BPC-157 acts more locally via growth factor upregulation and nitric oxide pathways; TB-500 acts more systemically by modulating the actin cytoskeleton and enabling cell migration. Both are for research use only.
Search any peptide research forum, browse any biohacking subreddit, or skim the growing pile of pre-print papers on soft-tissue repair, and you will find BPC-157 and TB-500 treated as a self-evident pair — the “Wolverine stack,” as some popular science writing has taken to calling it. Yet the majority of researchers and buyers who procure this combination cannot articulate why they complement each other at the mechanistic level, beyond the general intuition that “one does tissue repair and so does the other.”
That’s an incomplete picture. The two peptides have distinct origins, distinct primary mechanisms, and a distinct body of literature supporting them. Understanding those differences allows researchers to select the right compound for the right model — or to understand the rationale for studying them in combination.
For research use only. Nothing in this article constitutes medical advice or dosing guidance.
BPC-157 (Body Protection Compound-157) has the amino acid sequence GEPPPGKPADDAGLV and a molecular weight of approximately 1,419 Da. It is a synthetic 15-amino-acid (pentadecapeptide) fragment derived from a protein identified in human gastric juice. The “157” designation refers to its position in the larger parent protein sequence.
What makes BPC-157 unusual pharmacologically is its stability. Unlike most endogenous peptides, it is not rapidly degraded in the gastric environment — a property that has made it particularly interesting for gastrointestinal research models and has enabled both oral and parenteral administration routes in animal studies. It is not found in isolation in the body; it is a synthetic construct designed to preserve the pharmacologically active portion of the parent gastric protein.
TB-500 is a synthetic analogue of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found at high concentrations in platelets, wound fluid, and a wide range of human tissues. The specific TB-500 fragment (typically the actin-binding domain peptide, LKKTETQ, which corresponds to amino acids 17–23 of the full Tβ4 molecule) was identified as the pharmacologically critical region for wound healing activity.
TB-500 is not identical to full-length Tβ4 — it is a shorter synthetic fragment that reproduces the key functional domain while offering potentially different pharmacokinetic characteristics. Molecular weight is approximately 895 Da. Full-length Tβ4 (MW ~4,921 Da) is also used in research, and the two terms are sometimes used interchangeably in non-specialist writing, which can cause confusion when reviewing the literature.
| Property | BPC-157 | TB-500 (Tβ4 / Fragment) |
|---|---|---|
| Primary mechanism | VEGF/eNOS/NO pathway upregulation | G-actin sequestration; cell migration |
| Angiogenesis | Strong — via VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS signalling | Moderate — promotes new vessel formation in wound beds |
| Fibroblast modulation | Promotes fibroblast migration and collagen synthesis | Promotes keratinocyte and fibroblast migration |
| Growth factor activity | Stimulates EGR-1, upregulates VEGF at injury sites | Upregulates zyxin; modulates actin cytoskeleton dynamics |
| Anti-inflammatory | Yes — reduces pro-inflammatory cytokines | Yes — reduces macrophage and neutrophil infiltration |
| Primary research strength | Tendon, ligament, GI tract, nerve (rodent models) | Dermal wound healing, cardiac repair (rodent and clinical) |
| Action scope | Local/regional — strongest near administration site | Systemic — distributes broadly, mobilises cells to injury sites |
| Route studied | IP, oral (drinking water), topical | IP, topical, IV (in preclinical models) |
| Half-life (estimated preclinical) | Short; rapidly cleared | Moderate; Tβ4 has longer tissue residence |
The strongest BPC-157 literature comes from the laboratory of Predrag Šikiriċ at the University of Zagreb, whose group has published extensively across multiple tissue types.
In a 2003 study published in the Journal of Orthopaedic Research, BPC-157 was found to accelerate healing of transected Achilles tendon in rats, with improvements across biomechanical, functional, microscopic, and macroscopic measures. A 2010 paper in the same journal extended this to medial collateral ligament healing, showing efficacy via intraperitoneal, oral, and topical administration — a notable finding for route flexibility.
A 2017 review in the World Journal of Gastroenterology summarised BPC-157’s effects in colitis and ischaemia-reperfusion models, noting its consistent ability to attenuate ischaemic colitis and modulate collateral vessel formation. A 2016 PubMed review summarised its activity across the brain-gut axis, noting efficacy in GI tract healing, periodontitis, liver and pancreas lesions, and nerve repair.
A 2026 systematic review in Pharmaceuticals surveyed BPC-157’s role in complex musculoskeletal and junctional injuries, emphasising its cytoprotection concept — the ability to restore tissue integrity through systemic or local administration, without a carrier, across tendon, ligament, and muscle.
On mechanism, a 2025 paper in Pharmaceuticals (PMC) specifically addressed BPC-157’s interaction with the VEGF system and nitric oxide pathways, demonstrating its ability to modulate vasomotor tone and angiogenesis in a context-dependent manner — upregulating VEGF in the early days post-injury, then subsequently attenuating it.
Key caveat: The overwhelming majority of BPC-157 research has been conducted in rodent models, primarily rats. A small number of human clinical trials (for inflammatory bowel disease) are referenced, but the peptide has not completed phase III trials for any indication. Extrapolation to human outcomes must be done cautiously.
The foundational TB-500/Tβ4 wound healing paper is Malinda et al. (1999) in the FASEB Journal, which demonstrated that Tβ4 increased re-epithelialisation in rat full-thickness wound models by 42–61% over saline controls, with increased collagen deposition and angiogenesis.
A 2003 paper in Annals of the New York Academy of Sciences extended this to diabetic and aged mouse models, showing that both full-length Tβ4 and the seven-amino-acid actin-binding domain fragment (LKKTETQ) promoted wound repair — directly establishing the rationale for the TB-500 fragment.
The 2012 review in Clinical Ophthalmology summarised Tβ4’s multi-tissue wound healing activities, noting its roles in modulating the corneal inflammatory response, stimulating cell migration, promoting re-epithelialisation, and accelerating the repair cascade. The review also cited clinical trial data from two phase 2 studies of stasis and pressure ulcers, where Tβ4 accelerated healing by approximately one month in patients who did heal.
In cardiac research, a 2014 study in the American Journal of Physiology: Heart and Circulatory Physiology found that Tβ4 treatment post-myocardial infarction in murine models significantly reduced cardiac rupture, improved left ventricular function at five weeks, reduced inflammatory cell infiltration, and increased capillary density in the infarct border — representing one of the most robust cardiac repair findings in the Tβ4 literature.
Because these two peptides have different chemistries, the quality red flags differ slightly:
For BPC-157 (MW ~1,419 Da):
For TB-500 (MW ~895 Da for the fragment; ~4,921 Da for full Tβ4):
For a complete guide to reading COAs for either peptide, see our full article: How to Read a Peptide Certificate of Analysis.
The rationale for the BPC-157/TB-500 combination in research rests on mechanistic complementarity rather than redundancy:
BPC-157 is primarily a local growth factor and vascular tone modulator. Its strongest effects in animal models are observed at or near the administration site. It upregulates VEGF and nitric oxide production, recruits fibroblasts, and modulates the early angiogenic cascade. In tendon and ligament models, it functions as a site-directed stimulus for the healing response.
TB-500 is primarily a systemic cell mobiliser. By sequestering G-actin, it controls actin polymerisation dynamics, which directly governs cell motility. This enables progenitor cells, keratinocytes, and inflammatory cells to migrate more effectively to injury sites. Its cardiac repair effects — mediated by mobilising epicardial progenitors and reducing post-MI inflammation — reflect a broader, systemic action.
Together, the combination addresses two distinct phases of the tissue repair cascade: the local vascular and fibroblast recruitment phase (BPC-157) and the broader cell mobilisation and systemic anti-inflammatory phase (TB-500). These are not the same pathway, and published data do not suggest significant mechanistic overlap.
There are no published controlled studies of the combination as a formal stack. The rationale is inferential from individual compound mechanisms and represents an active area of interest in the peptide pharmacology literature.
Use this framework to determine which compound is more appropriate for a given research context:
Is the primary research focus tissue-local? ├─ YES → BPC-157 is likely the primary candidate │ Is the focus musculoskeletal (tendon/ligament)? → Strong literature support │ Is the focus GI / mucosal? → Strong literature support │ Is the focus peripheral nerve? → Moderate literature support └─ NO → Is the focus systemic or cardiac? ├─ YES (cardiac repair, post-MI) → Tβ4/TB-500 has stronger literature └─ YES (dermal wound healing) → Both compounds have literature Both + systemic cell mobilisation needed? → Combination may be relevantNo. They are chemically distinct peptides with different sequences, molecular weights, and primary mechanisms. BPC-157 is a 15-amino-acid fragment from a gastric protein; TB-500 is a synthetic analogue of the actin-binding domain of Thymosin Beta-4, a naturally occurring thymic peptide.
For BPC-157: Phase 2 clinical trial references for inflammatory bowel disease (PL 14736) exist in the literature, but the compound has not completed phase III development for any indication. No published controlled human data on musculoskeletal or other systemic effects. For TB-500 / Tβ4: Phase 2 clinical trial data exist for dermal wound healing (stasis and pressure ulcers), published in specialist wound care journals. All other data are preclinical (primarily rodent). All use should be for research purposes only.
No published data directly characterise interaction effects. Based on their mechanistic profiles — one operating primarily through nitric oxide/VEGF pathways, the other through actin cytoskeleton dynamics — there is no known pharmacological basis for antagonism. In vitro stability compatibility has not been formally published; for research purposes, they should be reconstituted and stored separately.
Because TB-500 is a synthetic fragment of Tβ4 and the terms are often used interchangeably in commercial contexts. Strictly speaking, they differ: TB-500 refers specifically to the synthetic fragment (often the 7-AA actin-binding domain), while Tβ4 may refer to the full 43-AA peptide. When purchasing, verify the amino acid sequence on the COA to confirm which form you are receiving.
Canada Peptide Supply carries both compounds, tested independently by a third-party laboratory with batch-specific COAs available for every lot. Shipped same-day from Toronto. Free Canada-wide shipping on orders over $200.
View our BPC-157 + TB-500 products →
Canada Peptide Supply carries BPC-157, TB-500, and the pre-blended BPC+TB stack. Every lot is independently tested via HPLC + mass spec. Shipped same-day from Toronto.